“Klow” BPC 157 10mg + GHK-CU 50mg + TB500 10mg + KPV 10mg – About This Product
The “Klow” peptide formulation is a research-grade composite blend that combines four bioactive peptides: BPC 157 peptide, GHK CU peptide, TB500 peptide, and KPV peptide. Each component has been independently studied in preclinical research for its proposed role in cellular repair, tissue responses, and molecular signaling pathways.
- BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from protective sequences found in human gastric juice. In preclinical models, BPC-157 has been proposed to influence nitric oxide signaling, vascular growth factor pathways, and fibroblast activity.
- GHK-Cu is a copper-complexed tripeptide (Gly-His-Lys) found naturally in human plasma that has been studied for its role in redox regulation and extracellular matrix remodeling.
- TB500 is a synthetic heptapeptide (7 amino acids; Ac-LKKTETQ) derived from the actin-binding region of the full 43-amino acid thymosin beta-4 protein. Important distinction: All published clinical research on thymosin beta-4 has employed the complete 43-amino acid peptide. TB500, as a 7-amino acid fragment, has not undergone equivalent human clinical evaluation.
- KPV peptide for research is a tripeptide (Lys-Pro-Val) derived from alpha-melanocyte-stimulating hormone (α-MSH) that has been investigated in preclinical models for potential anti-inflammatory effects.
The formulation is supplied as a lyophilized powder in sterile, sealed vials at research-grade purity, designed for use in controlled laboratory settings. Each peptide acts on distinct molecular targets and intracellular signaling pathways, making the combination suitable for research on multi-pathway cellular responses.
“Klow” BPC 157 10mg + GHK-CU 50mg + TB500 10mg + KPV 10mg – Key Features and Benefits
- Multi-Peptide Research Formulation — Combines BPC 157 peptide, GHK-Cu peptide, TB500 peptide, and KPV peptide, each studied independently for distinct roles in cellular processes
- Research-Grade Composition — Lyophilized powder verified for identity and purity using high-performance liquid chromatography (HPLC) and mass spectrometry (MS)
- Convenient Laboratory Format — Provided in sterile vials requiring reconstitution with sterile diluent for use in preclinical research protocols
- Distinct Signaling Pathways — Each component peptide operates through separate molecular targets, allowing researchers to investigate parallel and divergent signaling effects
- Multiple Research Applications — Suitable for in vitro cell culture systems, ex vivo tissue models, and animal studies examining coordinated biological responses
- Stable Storage Profile — Lyophilized format maintains peptide stability under standard refrigeration conditions
- Quality Documentation — Each batch includes analytical verification; certificates of analysis available upon request
- For Laboratory Research Use Only — Intended exclusively for regulated research environments and qualified investigators conducting preclinical studies
“Klow” BPC 157 10mg + GHK-CU 50mg + TB500 10mg + KPV 10mg – Mechanism & Research Applications
The BPC 157 peptide, GHK-Cu peptide, TB500 peptide, and KPV peptide formulation has been examined in preclinical research for distinct proposed mechanisms. BPC-157 has been investigated for its potential role in modulating nitric oxide signaling and vascular endothelial growth factor (VEGF) pathways in animal wound models.
Furthermore, GHK-Cu has been studied for its proposed involvement in regulating collagen synthesis and extracellular matrix remodeling through copper-dependent enzyme mechanisms. TB500 has been evaluated for its potential effects on actin dynamics and cellular migration in animal models, but all published clinical research has used the full 43-amino-acid thymosin beta-4, not the TB500 fragment.
Moreover, KPV has been investigated in preclinical models for potential anti-inflammatory effects, primarily through inhibition of intracellular NF-κB and MAP kinase signaling pathways, independent of melanocortin receptor mechanisms.
In laboratory research, these peptides have been examined for coordinated effects on inflammation regulation, angiogenesis, fibroblast activity, and cellular stress responses in animal and cell culture models. However, combination-specific effects of all four peptides have not been formally studied, and no human clinical trials have evaluated this formulation or the four-peptide combination in humans.
The convergence of these proposed mechanisms supports investigation into multi-layered signaling systems involved in cellular and tissue responses within controlled experimental settings.
“Klow” BPC 157 10mg + GHK-CU 50mg + TB500 10mg + KPV 10mg – Dosing & Observed Effects in Research
Human safe dosing has not been established for any of these peptides, and animal dosing cannot be directly translated to humans. However, research provides that the preclinical dosing ranges of these research-grade peptides are as follows:
- BPC-157: Animal models employ doses ranging from 6 to 50 µg/kg body weight via intraperitoneal, intramuscular, or oral routes. Limited human pilot data: one study (Lee et al., 2024) examined intravesical BPC-157 injection at 10 mg in 12 patients with interstitial cystitis.
- TB500: Animal studies typically use 250–500 mcg per injection or 6 mg/kg body weight, administered 2–3 times weekly. Important note: Clinical evidence for TB500 specifically is minimal. Two Phase 2 trials examined topical full-length thymosin beta-4 (not TB500) in wound healing, showing modest results (approximately 25% complete healing in 3 months for venous stasis ulcers). No human clinical data exists for the TB500 fragment.
- GHK-Cu: Research concentrations vary by application. Tissue culture studies have employed concentrations around 0.3 mg/mL in specific experimental contexts (e.g., intra-articular injection in mouse models). This represents one specific application and should not be generalized.
- KPV: Animal studies have employed 0.1 μg intravenously every other day. In vitro studies use concentrations ranging from 1–100 µM. No human clinical trials have evaluated KPV dosing or safety.
Notably, the preclinical research observations in animal and cell culture models have included reports of enhanced cellular migration, increased angiogenesis markers, collagen deposition, and reduced inflammatory markers.
However, all observed effects derive exclusively from animal models and in vitro studies. Human clinical data are limited to a single 12-patient pilot study of BPC-157 for interstitial cystitis. No human clinical data exists for TB500, GHK-Cu, or KPV as standalone agents, and no human studies have evaluated the four-peptide combination.
“Klow” BPC 157 10mg + GHK-CU 50mg + TB500 10mg + KPV 10mg – Storage, Safety & References
Store the lyophilized peptide formulation at 2–8°C in a dry, protected location away from light and moisture. Avoid freeze-thaw cycles to preserve peptide integrity. Once reconstituted with sterile diluent, refrigerate and use within two weeks. Specific shelf-life may vary depending on diluent type and storage conditions.
For quality verification, request certificates of analysis from suppliers confirming identity (HPLC/MS), purity (target >95%), sterility, absence of endotoxins, and absence of contaminants. The research peptide supply chain is largely unregulated. Third-party testing is recommended for critical applications.
Safety Considerations
Preclinical studies of individual peptides have not reported significant acute toxicity. However, human safety profiles are unknown, as these compounds have not undergone comprehensive clinical evaluation.
- TB500 and injectable GHK-Cu are prohibited for compounding under current FDA regulations due to identified safety risks and insufficient human safety data.
- BPC-157 is not FDA-approved and is subject to FDA warning letters against marketing for human use.
- KPV has been evaluated only in animal and cell culture research with zero human clinical trials.
Notably, no long-term safety data exists for any of these compounds in humans. No safety data exists for the four-peptide combination. This product must be used exclusively in regulated laboratory settings for in vitro and animal model research by qualified investigators.
References
https://pubmed.ncbi.nlm.nih.gov/36588717
https://pubmed.ncbi.nlm.nih.gov/40005999
https://pubmed.ncbi.nlm.nih.gov/39325560
https://pubmed.ncbi.nlm.nih.gov/22074294
https://pmc.ncbi.nlm.nih.gov/articles/PMC5498804
https://jpet.aspetjournals.org/article/S0022-3565(24)30846-8/abstract
https://pubmed.ncbi.nlm.nih.gov/18612139
https://pubmed.ncbi.nlm.nih.gov/18644225